KANSAS OFFICE of
  REVISOR of STATUTES

  

Home >> Statutes >> Back


Click to open printable format in new window.Printable Format
 | Next

65-4109. Substances included in schedule III. (a) The controlled substances listed in this section are included in schedule III and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.

(b) Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

  • (1)    Any compound, mixture or preparation containing:
  •         (A)   Amobarbital2126
  •         (B)   Secobarbital2316
  •         (C)   Pentobarbital2271
  •                 or any salt thereof and one or more other active medicinal ingredients
  •                 which are not listed in any schedule
  • (2)    Any suppository dosage form containing:
  •         (A)   Amobarbital2126
  •         (B)   Secobarbital2316
  •         (C)   Pentobarbital2271
  •                 or any salt of any of these drugs and approved by the Food and Drug
  •                 Administration for marketing only as a suppository.
  • (3)    Any substance which contains any quantity of a derivative of barbituric acid, or any
  •                 salt of a derivative of barbituric acid, except those substances which are specifically
  •                 listed in other schedules2100
  • (4)    Chlorhexadol2510
  • (5)    Lysergic acid7300
  • (6)    Lysergic acid amide7310
  • (7)    Methyprylon2575
  • (8)    Sulfondiethylmethane2600
  • (9)    Sulfonethylmethane2605
  • (10)  Sulfonmethane2610
  • (11)  Tiletamine and zolazepam or any salt thereof7295
  •          Some trade or other names for a tiletamine-zolazepam combination product: Telazol
  •          Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
  •          trimethylpyrazolo-[3,4-e][1,4]-diazepin-7(1H)-one, flupyrazapon
  • (12)  Ketamine, its salts, isomers, and salts of isomers7285
  •          Some other names for ketamine: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone
  • (13)  Gamma hydroxybutyric acid, any salt, hydroxybutyric compound, derivative or
  •          of gamma hydroxybutyric acid contained in a drug product for which an application has
  •          been approved under section 505 of the federal food, drug and cosmetic act
  • (14)  Embutramide22020
  • (15)  Perampanel, its salts, isomers, and salts of isomers2261
  •          Some other names for perampanel: 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2 dihydropyridin-3-yl) benzonitrile
  •        (c)  Nalorphine9400

(d)  Any material, compound, mixture or preparation containing any of the following narcotic drugs or any salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

  • (1)   Not more than 1.8 grams of codeine or any of its salts per 100 milliliters or not more than 90
  •         milligrams per dosage unit with an equal or greater quantity of an isoquinoline alkaloid of opium9803
  • (2)   not more than 1.8 grams of codeine or any of its salts per 100 milliliters or not more than 90
  •         milligrams per dosage unit with one or more active, nonnarcotic ingredients in
  •         recognized therapeutic amounts9804
  • (3)   not more than 1.8 grams of dihydrocodeine or any of its salts per 100 milliliters or
  •         not more than 90 milligrams per dosage unit with one or more
  •         active, nonnarcotic ingredients in recognized therapeutic amounts9807
  • (4)   not more than 300 milligrams of ethylmorphine or any of its salts per 100 milliliters or
  •         not more than 15 milligrams per dosage unit with one or more active,
  •         nonnarcotic ingredients in recognized therapeutic amounts9808
  • (5)   not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more
  •         than 25 milligrams per dosage unit with one or more active, nonnarcotic
  •         ingredients in recognized therapeutic amounts9809
  • (6)   not more than 50 milligrams of morphine or any of its salts per 100 milliliters or per 100 grams
  •         with one or more active, nonnarcotic ingredients in recognized therapeutic amounts9810
  • (7)   any material, compound, mixture or preparation containing any of the following narcotic
  •         drugs or their salts, as set forth below:
  •         (A)   Buprenorphine9064

(e)  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

  • (1)   Those compounds, mixtures or preparations in dosage unit form containing any stimulant substance
  •         listed in schedule II, which compounds, mixtures or preparations were listed on
  •         August 25, 1971, as excepted compounds under section 308.32 of title 21 of the code of federal
  •         regulations, and any other drug of the quantitive composition shown in that list for those
  •         drugs or which is the same, except that it contains a lesser quantity of controlled substances1405
  • (2)   Benzphetamine1228
  • (3)   Chlorphentermine1645
  • (4)   Chlortermine1647
  • (5)   Phendimetrazine1615
  •        (f)  Anabolic steroids4000

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth, and includes:

  • (1)    3β,17-dihydroxy-5a-androstane
  • (2)    3α,17β-dihydroxy-5a-androstane
  • (3)    5a-androstan-3,17-dione
  • (4)    1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene)
  • (5)    1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene)
  • (6)    4-androstenediol (3β,17β-dihydroxy-androst-4-ene)
  • (7)    5-androstenediol (3β,17β-dihydroxy-androst-5-ene)
  • (8)    1-androstenedione ([5α]-androst-1-en-3,17-dione)
  • (9)    4-androstenedione (androst-4-en-3,17-dione)
  • (10)  5-androstenedione (androst-5-en-3,17-dione)
  • (11)  bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one)
  • (12)  boldenone (17β-hydroxyandrost-1,4-diene-3-one)
  • (13)  boldione (androsta-1,4-diene-3,17-dione)
  • (14)  calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one)
  • (15)  clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one)
  • (16)  dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one)
  • (17)  desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) (also known as "madol")
  • (18)  Δ1-dihydrotestosterone (17β-hydroxy-5α-androst-1-en-3-one) (also known as "1-testosterone")
  • (19)  4-dihydrotestosterone (17β-hydroxy-androstan-3-one)
  • (20)  drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one)
  • (21)  ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene)
  • (22)  fluoxymesterone (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one)
  • (23)  formebolone (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one)
  • (24)  furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]-furazan)
  • (25)  13β-ethyl-17β-hydroxygon-4-en-3-one
  • (26)  4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one)
  • (27)  4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one)
  • (28)  mestanolone (17α-methyl-17β-hydroxy-5-androstan-3-one)
  • (29)  mesterolone (1α-methyl-17β-hydroxy-[5α]-androstan-3-one)
  • (30)  methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one)
  • (31)  methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene)
  • (32)  methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one)
  • (33)  methenolone (1-methyl-17β-hydroxy-5α-androst-1-en-3-one)
  • (34)  17α-methyl-3β,17β-dihydroxy-5a-androstane
  • (35)  17α-methyl-3α,17β-dihydroxy-5a-androstane
  • (36)  17α-methyl-3β,17β-dihydroxyandrost-4-ene
  • (37)  17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one)
  • (38)  methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one)
  • (39)  methyltrienolone (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one)
  • (40)  methyltestosterone (17α-methyl-17β-hydroxyandrost-4-en-3-one)
  • (41)  mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one)
  • (42)  17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also known
  •          as "17-α-methyl-1-testosterone")
  • (43)  nandrolone (17β-hydroxyestr-4-en-3-one)
  • (44)  19-nor-4-androstenediol (3β, 17β-dihydroxyestr-4-ene)
  • (45)  19-nor-4-androstenediol (3α, 17β-dihydroxyestr-4-ene)
  • (46)  19-nor-5-androstenediol (3β, 17β-dihydroxyestr-5-ene)
  • (47)  19-nor-5-androstenediol (3α, 17β-dihydroxyestr-5-ene)
  • (48)  19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
  • (49)  19-nor-4-androstenedione (estr-4-en-3,17-dione)
  • (50)  19-nor-5-androstenedione (estr-5-en-3,17-dione)
  • (51)  norbolethone (13β, 17α-diethyl-17β-hydroxygon-4-en-3-one)
  • (52)  norclostebol (4-chloro-17β-hydroxyestr-4-en-3-one)
  • (53)  norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-one)
  • (54)  normethandrolone (17α-methyl-17β-hydroxyestr-4-en-3-one)
  • (55)  oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one)
  • (56)  oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one)
  • (57)  oxymetholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one)
  • (58)  prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole)
  • (59)  stanozolol (17α-methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole)
  • (60)  stenbolone (17β-hydroxy-2-methyl-[5α]-androst-1-en-3-one)
  • (61)  testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone)
  • (62)  testosterone (17β-hydroxyandrost-4-en-3-one)
  • (63)  tetrahydrogestrinone (13β, 17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one)
  • (64)  trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
  • (65)  any salt, ester, or isomer of a drug or substance described or listed in this paragraph,
  •          if that salt, ester, or isomer promotes muscle growth.
  •          (A)   Except as provided in (B), such term does not include an anabolic steroid which is
  •                   expressly intended for administration through implants to cattle or other nonhuman
  •                   species and which has been approved by the United States' secretary of health and
  •                   human services for such administration.
  •          (B)   If any person prescribes, dispenses or distributes such steroid for human use, such person
  •                   shall be considered to have prescribed, dispensed or distributed an anabolic steroid within
  •                   the meaning of this subsection (f).

(g)  Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substance, its salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

  • (1)    Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United
  •          States food and drug administration approved product7369
  •          Some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro -6-6-9-trimethyl-3-
  •          pentyl-6H-dibenzo(b,d)pyran-1-0l, or (-)-delta-9-(trans)-tetrahydrocannabinol.

(h)  The board may except by rule any compound, mixture or preparation containing any stimulant or depressant substance listed in subsection (b) from the application of all or any part of this act if the compound, mixture or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.

History: L. 1972, ch. 234, § 9; L. 1974, ch. 258, § 4; L. 1978, ch. 257, § 2; L. 1982, ch. 269, § 4; L. 1985, ch. 220, § 3; L. 1989, ch. 200, § 3; L. 1991, ch. 199, § 3; L. 1992, ch. 174, § 3; L. 2000, ch. 108, § 3; L. 2001, ch. 171, § 4; L. 2011, ch. 83, § 5; L. 2014, ch. 79, § 2; L. 2015, ch. 27, § 3; L. 2016, ch. 95, § 3; L. 2018, ch. 101, § 3; May 24.

Revisor's Note:

Section was also amended by L. 2011, ch. 10, § 3, but that version was repealed by L. 2011, ch. 83, § 9.

Section was not amended in the 2016 session.

CASE ANNOTATIONS

1. Appeal from conviction for sale of narcotic drugs; no error in overruling motions for acquittal, continuance or for new trial. State v. Holt, 221 Kan. 696, 561 P.2d 435.

2. Possession of the narcotic in Lortab is a felony under K.S.A. 65-4160. State v. Surowski, 42 Kan. App. 2d 304, 212 P.3d 229 (2009).


Previous | Next


LEGISLATIVE COORDINATING COUNCIL
  01/08/2026 Meeting Notice Agenda
Item 1 Proposed Minutes December 22, 2025
Item 2 LCC Policy 38 Amend
Item 4 LCC Memo KLISS Update
  12/22/2025 Meeting Notice Agenda
Item 1 PROPOSED MINUTES November 5, 2025
  11/05/2025 Meeting Notice Agenda
Item 1 Proposed Minutes October 13, 2025
Item 3 Legislative branch holidays for 2026
Item 6 LCC Steering Committee Report final
Item 7 LCC Policy 33 and 38 matters
  10/13/2025 Meeting Notice Agenda
Item 1 Proposed Minutes September 24, 2025
Item 3 Consideration and approval of Legislative agency budgets
Item 4 Document Packet Pricing
Item 5 2026 KSA prices annotated
  09/24/2025 Meeting Notice Agenda
Item 1 Proposed Minutes August 14, 2025
Item 2 Additional interim committees, topics and meeting days
Item 3 Notices and intention to dispose of school buildings
Item 5 Pricing for Legislative Highlights and Summary of Legislation Documents
Item 6 Session Pay Plan
Item 8 Subscription for upgrades and support of virtual statehouse system
  08/14/2025 Meeting Notice Agenda
Item 1 Proposed Minutes July 7, 2025
Item 2 Delperdang and Shallenburger interm requests
Item 4 USD 220 Ashland Schools Memo
Item 5 Permanent Journal Order LCC 2025
Item 6 KLOIS LAS Data Center Upgrade
Item 7 KLISS Update 08142025
  07/07/2025 Meeting Notice Agenda
Item 2 Water Program Task Force Meeting Days
Item 3 Staff Budget Preparation
Item 5 KLISS Modernization
Item 7 House Voting Boards
Item 9 KHP LCC Capitol Police Transition Briefing
  05/08/2025 Meeting Notice Agenda
  03/17/2025 Meeting Notice Agenda

  LCC Policies

REVISOR OF STATUTES
  2025 Interim Studies - Staff Assignments
  Chapter 72 Statute Transfer List
  Kansas School Equity & Enhancement Act
  Gannon v. State
  A Summary of Special Sessions in Kansas
  Bill Brief for Senate Bill No. 1
  Bill Brief for House Bill No. 2001
  2025 New, Amended & Repealed Statutes By Bill
  2025 New, Amended & Repealed Statutes By KSA
  2024 New, Amended & Repealed Statutes By Bill
  2024 New, Amended & Repealed Statutes By KSA
  2023 New, Amended & Repealed Statutes By Bill
  2023 New, Amended & Repealed Statutes By KSA
USEFUL LINKS
Session Laws

OTHER LEGISLATIVE SITES
Kansas Legislature
Administrative Services
Division of Post Audit
Research Department